Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + SOX for Locally Advanced Gastric Cancer
NCT05602935Phase 2Active, not recruiting
- Sponsor
- The Second Affiliated Hospital of Fujian Medical University
- Start
- Sep 2020
- Primary completion
- Mar 2022
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab in gastric cancer (GC), gastroesophageal junction adenocarcinoma, sponsored by The Second Affiliated Hospital of Fujian Medical University. Started Sep 2020; status: active, not recruiting.
02
Drugs
camrelizumab
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT05602935.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05602935.